公开(公告)号：US11951146B2

公开(公告)日：2024-04-09

申请号：US17534292

申请日：2021-11-23

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas Ichim ,  Timothy G. Dixon ,  Famela Ramos ,  Wais Kaihani

IPC分类号： A61K36/82 ,  A61K31/09 ,  A61K31/122 ,  A61K31/155 ,  A61K31/26 ,  A61K31/352 ,  A61K36/31 ,  A61K36/45 ,  A61K36/71 ,  A61P31/14 ,  A61P37/04

CPC分类号： A61K36/82 ,  A61K31/09 ,  A61K31/122 ,  A61K31/155 ,  A61K31/26 ,  A61K31/352 ,  A61K36/31 ,  A61K36/45 ,  A61K36/71 ,  A61P37/04

摘要： Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of pterostilbene, Nigella sativa extract, green tea extract, and broccoli. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.

公开(公告)号：US20220193127A1

公开(公告)日：2022-06-23

申请号：US17556985

申请日：2021-12-20

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas Ichim ,  Timothy G. Dixon ,  Famela Ramos ,  Wais Kaihani ,  James Veltmeyer ,  Kalina O'Connor

IPC分类号： A61K35/16 ,  A61P25/36 ,  G01N33/68

摘要： Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.

公开(公告)号：US20220160809A1

公开(公告)日：2022-05-26

申请号：US17534292

申请日：2021-11-23

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas Ichim ,  Timothy G. Dixon ,  Famela Ramos ,  Wais Kaihani

IPC分类号： A61K36/82 ,  A61K31/155 ,  A61K36/45 ,  A61K36/31 ,  A61K36/71 ,  A61K31/352 ,  A61K31/122 ,  A61K31/09 ,  A61K31/26 ,  A61P37/04

摘要： Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.

公开(公告)号：US20230085607A1

公开(公告)日：2023-03-16

申请号：US17931872

申请日：2022-09-13

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas E. Ichim ,  Famela Ramos ,  James Veltmeyer ,  Timothy G. Dixon ,  Feng Lin ,  Wais Kaihani

IPC分类号： A61K31/7048 ,  A61K31/353 ,  A61K31/09 ,  A61K31/122 ,  A61K31/26 ,  A61K36/82 ,  A61K36/45 ,  A61K36/71 ,  A61K36/31

摘要： Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

公开(公告)号：US20220370499A1

公开(公告)日：2022-11-24

申请号：US17748997

申请日：2022-05-19

申请人： Therapeutic Solutions International, Inc.

发明人： Thomas E. Ichim ,  Famela Ramos ,  James Veltmeyer ,  Timothy G. Dixon ,  Feng Lin ,  Wais Kaihani

IPC分类号： A61K35/17 ,  C12N5/0784 ,  C12N5/0789 ,  A61K39/00 ,  A61P37/06

摘要： Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α-Gal epitope (Galα1,3Galα1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.